Published in Clin Exp Immunol on June 01, 2006
The alternative complement pathway revisited. J Cell Mol Med (2008) 1.62
Recent developments in low molecular weight complement inhibitors. Mol Immunol (2009) 1.23
New concepts of complement in allorecognition and graft rejection. Cell Immunol (2007) 1.02
The alternative pathway is required, but not alone sufficient, for retinal pathology in mouse laser-induced choroidal neovascularization. Mol Immunol (2011) 0.98
Systemic human CR2-targeted complement alternative pathway inhibitor ameliorates mouse laser-induced choroidal neovascularization. J Ocul Pharmacol Ther (2012) 0.96
Lack of the pattern recognition molecule mannose-binding lectin increases susceptibility to influenza A virus infection. BMC Immunol (2010) 0.93
Alternative complement pathway deficiency ameliorates chronic smoke-induced functional and morphological ocular injury. PLoS One (2013) 0.88
The role of properdin in zymosan- and Escherichia coli-induced complement activation. J Immunol (2012) 0.87
Local production of the alternative pathway component factor B is sufficient to promote laser-induced choroidal neovascularization. Invest Ophthalmol Vis Sci (2015) 0.81
Complement. First of two parts. N Engl J Med (2001) 11.16
Studies on human antibodies. VI. Selective variations in subgroup composition and genetic markers. J Exp Med (1968) 5.72
Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med (1996) 2.67
Mannose-binding lectin deficiency--revisited. Mol Immunol (2003) 2.52
The role of mannose-binding lectin in health and disease. Mol Immunol (2003) 2.41
Mannose binding lectin gene polymorphisms confer a major risk for severe infections after liver transplantation. Gastroenterology (2005) 2.30
Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury. Proc Natl Acad Sci U S A (2004) 2.30
Intestinal reperfusion injury is mediated by IgM and complement. J Appl Physiol (1985) (1999) 2.13
Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol (1985) 2.06
Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q. J Immunol (2005) 2.02
Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immunol (2005) 1.89
Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol (2000) 1.86
Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods (2004) 1.78
Most Mycobacterium leprae carbohydrate-reactive monoclonal antibodies are directed to lipoarabinomannan. Infect Immun (1987) 1.73
L-ficolin is a pattern recognition molecule specific for acetyl groups. J Biol Chem (2004) 1.70
The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol (2004) 1.65
Clinical manifestations of mannan-binding lectin deficiency. Mol Immunol (2006) 1.51
An assay for the mannan-binding lectin pathway of complement activation. J Immunol Methods (2001) 1.50
Dual role of mannan-binding protein in infections: another case of heterosis? Eur J Immunogenet (1994) 1.50
Role for the alternative complement pathway in ischemia/reperfusion injury. Am J Pathol (2003) 1.49
Functional characterization of the lectin pathway of complement in human serum. Mol Immunol (2003) 1.48
Mannan-binding lectin recognizes structures on ischaemic reperfused mouse kidneys and is implicated in tissue injury. Scand J Immunol (2005) 1.44
Complement in inflammatory tissue damage and disease. Trends Immunol (2002) 1.43
Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol (2001) 1.41
Disease-associated mutations in human mannose-binding lectin compromise oligomerization and activity of the final protein. J Biol Chem (2004) 1.40
Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrol Dial Transplant (1998) 1.31
Assays for the functional activity of the mannan-binding lectin pathway of complement activation. Immunobiology (2002) 1.29
Antibody-mediated activation of the classical pathway of complement may compensate for mannose-binding lectin deficiency. Eur J Immunol (2004) 1.15
Human Mannose-binding Lectin in Immunity: Friend, Foe, or Both? J Exp Med (2004) 1.12
Ischaemia-reperfusion is an event triggered by immune complexes and complement. Br J Surg (2003) 1.12
Ficolins and the lectin complement pathway. Immunol Rev (2001) 1.10
Mechanism of complement activation and its role in the inflammatory response after thoracoabdominal aortic aneurysm repair. Circulation (2003) 1.07
Evidence that complement protein C1q interacts with C-reactive protein through its globular head region. J Immunol (2006) 1.05
Deposition of mannan binding protein and mannan binding protein-mediated complement activation in the glomeruli of patients with IgA nephropathy. Nephron (1998) 1.02
Circulating beta (1-3) glucan and immunoglobulin G subclass antibodies to Candida albicans cell wall antigens in patients with systemic candidiasis. Clin Diagn Lab Immunol (2004) 0.96
IgG and complement-mediated tissue damage in the absence of C2: evidence of a functionally active C2-bypass pathway in a guinea pig model. J Immunol (1999) 0.91
Complement activation through the lectin pathway in patients with Henoch-Schönlein purpura nephritis. Am J Kidney Dis (2000) 0.89
Identification of human mannose binding lectin (MBL) recognition sites for novel inhibitory antibodies. Hybrid Hybridomics (2002) 0.88
Demonstration of antibodies reacting with different determinants on Mycobacterium leprae antigen 7. Int J Lepr Other Mycobact Dis (1981) 0.85
Intracellular pH. Physiol Rev (1981) 16.27
Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol (1995) 3.30
Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. JAMA (2001) 2.90
Dual effect of CCR5 delta 32 gene deletion in HIV-1-infected patients. Copenhagen AIDS Study Group. Lancet (1997) 2.70
Intracellular pH and intracellular buffering power of the cat brain. Am J Physiol (1965) 2.47
Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest (2000) 2.45
Neutrophil-derived 5'-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation. J Exp Med (1998) 2.33
A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein. Immunogenetics (1994) 2.31
Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride: a meta-analysis. JAMA (1998) 2.24
Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc Natl Acad Sci U S A (1999) 2.21
Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation (1998) 2.14
Different molecular events result in low protein levels of mannan-binding lectin in populations from southeast Africa and South America. J Immunol (1998) 2.11
Comparison of predictive models for postoperative nausea and vomiting. Br J Anaesth (2002) 2.06
Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol (1985) 2.06
Intracellular pH and buffering power of rat muscle. Am J Physiol (1971) 2.05
Persistent complement activation in submucosal blood vessels of active inflammatory bowel disease: immunohistochemical evidence. Gastroenterology (1989) 1.93
Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H. Infect Immun (1999) 1.87
Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol (2000) 1.86
Biochemical and kinetic analyses of NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Virology (1998) 1.81
Comparison of microelectrode, DMO, and methylamine methods for measuring intracellular pH. Am J Physiol (1976) 1.80
Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods (2004) 1.78
Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma. Scand J Immunol (1985) 1.72
pH regulation in barnacle muscle fibers: dependence on intracellular and extracellular pH. Am J Physiol (1979) 1.70
Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation (2001) 1.70
The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol (2004) 1.65
Intracellular pH and distribution of weak acids across cell membranes. A study of D- and L-lactate and of DMO in rat diaphragm. J Physiol (1975) 1.62
Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study. Eur Respir J (2009) 1.62
Association of mannose-binding-lectin deficiency with severe atherosclerosis. Lancet (1998) 1.62
A pathogenic role for secretory IgA in IgA nephropathy. Kidney Int (2006) 1.58
Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest (1995) 1.57
The intracellular pH of frog skeletal muscle: its regulation in isotonic solutions. J Physiol (1983) 1.57
Influence of cyclic AMP on intracellular pH regulation and chloride fluxes in barnacle muscle fibers. Nature (1978) 1.56
Early renal ischemia-reperfusion injury in humans is dominated by IL-6 release from the allograft. Am J Transplant (2009) 1.53
Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis. Gastroenterology (1990) 1.53
The impact of FCN2 polymorphisms and haplotypes on the Ficolin-2 serum levels. Scand J Immunol (2007) 1.51
Extracorporeal membrane oxygenation using a centrifugal pump and a servo regulator to prevent negative inlet pressure. Ann Thorac Surg (1997) 1.50
Alcohol consumption is associated with decreased risk of rheumatoid arthritis: results from two Scandinavian case-control studies. Ann Rheum Dis (2008) 1.49
High and low heparin dose with heparin-coated cardiopulmonary bypass: activation of complement and granulocytes. Ann Thorac Surg (1995) 1.48
Different oxygenators for cardiopulmonary bypass lead to varying degrees of human complement activation in vitro. J Thorac Cardiovasc Surg (1989) 1.45
Complement activation and endotoxin levels in systemic meningococcal disease. J Infect Dis (1989) 1.44
Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol (2001) 1.41
Surgically created fourth-third cranial nerve communication: temporary success in a child with bilateral third nerve hamartomas. Case report. J Neurosurg (1999) 1.39
The association of variant mannose-binding lectin genotypes with radiographic outcome in rheumatoid arthritis. Arthritis Rheum (2000) 1.37
Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand J Immunol (2009) 1.37
Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur J Immunol (1991) 1.36
Inhibition of complement C5 reduces local and remote organ injury after intestinal ischemia/reperfusion in the rat. Gastroenterology (2001) 1.35
pH regulation in barnacle muscle fibers: dependence on extracellular sodium and bicarbonate. Am J Physiol (1981) 1.33
Endothelial oxidative stress activates the lectin complement pathway: role of cytokeratin 1. Am J Pathol (2001) 1.33
Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation. Clin Exp Immunol (1988) 1.32
Systemic meningococcal disease: a model infection to study acute endotoxinemia in man. Prog Clin Biol Res (1988) 1.30
Regulation of intracellular pH in human neutrophils. J Gen Physiol (1985) 1.29
Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality. Gut (1997) 1.27
Complement S-protein (vitronectin) is associated with cytolytic membrane-bound C5b-9 complexes. Clin Exp Immunol (1988) 1.25
Cardiovascular effects of acute hypercholesterolemia in rabbits. Reversal with lovastatin treatment. J Clin Invest (1989) 1.24
Hypoxia enhances induction of endothelial ICAM-1: role for metabolic acidosis and proteasomes. Am J Physiol (1997) 1.20
Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex. Arthritis Rheum (1986) 1.20
The artificial surface-induced whole blood inflammatory reaction revealed by increases in a series of chemokines and growth factors is largely complement dependent. J Biomed Mater Res A (2008) 1.20
The structure and synthesis of malformin A. Proc Natl Acad Sci U S A (1974) 1.18
Systemic complement activation following human acute ischaemic stroke. Clin Exp Immunol (2004) 1.16
Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Scand J Immunol (1988) 1.15
Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Clin Exp Immunol (1993) 1.15
Complement activation following oxidative stress. Mol Immunol (2000) 1.14
Synergistic deposition of C4d by complement-activating and non-activating antibodies in cardiac transplants. Am J Transplant (2007) 1.13
Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. Blood (1999) 1.13
Diagnostic efficacy and prognostic value of serum procalcitonin concentration in patients with suspected sepsis. J Intensive Care Med (2008) 1.12
The buffer value of weak acids and bases: origin of the concept, and first mathematical derivation and application to physico-chemical systems. The work of M. Koppel and K. Spiro (1914). Respir Physiol (1980) 1.12
Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J Am Soc Nephrol (2000) 1.12
Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. Am J Physiol Heart Circ Physiol (2000) 1.12
Cardiac-cardiovascular reflexes induced by hydrogen peroxide in cats. Am J Physiol (1995) 1.11
Differences in complement activation between complement-resistant and complement-sensitive Moraxella (Branhamella) catarrhalis strains occur at the level of membrane attack complex formation. Infect Immun (1994) 1.10
Acute phase haemolysis in chronic cold agglutinin disease. Scand J Immunol (2001) 1.10
Mannose-binding lectin plays a critical role in myocardial ischaemia and reperfusion injury in a mouse model of diabetes. Diabetologia (2008) 1.08
Heparin-binding properties of vitronectin are linked to complex formation as illustrated by in vitro polymerization and binding to the terminal complement complex. J Biol Chem (1992) 1.08
Reoxygenation of hypoxic human umbilical vein endothelial cells activates the classic complement pathway. Circulation (1997) 1.07
Ischemia- and reperfusion-sensitive cardiac sympathetic afferents: influence of H2O2 and hydroxyl radicals. Am J Physiol (1995) 1.07
Molecular basis of hereditary C1q deficiency--revisited: identification of several novel disease-causing mutations. Genes Immun (2011) 1.06
Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type II (porcine dense deposit disease). Am J Pathol (1993) 1.06
Hyperbaric oxygen downregulates ICAM-1 expression induced by hypoxia and hypoglycemia: the role of NOS. Am J Physiol Cell Physiol (2000) 1.06
Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol (1995) 1.06
Surface epithelium related activation of complement differs in Crohn's disease and ulcerative colitis. Gut (1992) 1.04
STUDIES OF THERMAL INJURY. VI. HYPERPOTASSEMIA CAUSED BY CUTANEOUS EXPOSURE TO EXCESSIVE HEAT. J Clin Invest (1947) 1.04
Terminal complement pathway activation and low lysis inhibitors in rheumatoid arthritis synovial fluid. J Rheumatol (1995) 1.03
Ischemically sensitive abdominal visceral afferents: response to cyclooxygenase blockade. Am J Physiol (1991) 1.02
Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro. Clin Exp Immunol (1986) 1.01
IMP and AMP deaminase in reperfusion injury down-regulates neutrophil recruitment. Proc Natl Acad Sci U S A (2000) 1.01
Biochemical and structural analysis of the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. J Viral Hepat (2000) 1.01
Complement activation in patients with congestive heart failure: effect of high-dose intravenous immunoglobulin treatment. Circulation (2001) 1.01
Early- and late-phase activation of complement evaluated by plasma levels of C3d,g and the terminal complement complex. Complement (1985) 1.00
The intracellular pH of frog skeletal muscle: its regulation in hypertonic solutions. J Physiol (1983) 1.00
Intrathecal activation of the complement system and disability in multiple sclerosis. J Neurol Sci (1998) 0.99
Heparin-coated cardiopulmonary bypass equipment. I. Biocompatibility markers and development of complications in a high-risk population. J Thorac Cardiovasc Surg (1999) 0.99
Autoantibodies against mannose-binding lectin in systemic lupus erythematosus. Clin Exp Immunol (2003) 0.99
Complement activation in synovial fluid and tissue from patients with juvenile rheumatoid arthritis. Arthritis Rheum (1986) 0.98